Rivaroxaban: Expanded Role in Cardiovascular Disease Management—A Literature Review | Zendy

Muhammad Ajmal | Zendy; Jacob Friedman | Zendy; Qurat Ul Ain Riaz Sipra | Zendy; Tom Lassar | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Rivaroxaban: Expanded Role in Cardiovascular Disease Management—A Literature Review

Author(s) -

Muhammad Ajmal,

Jacob Friedman,

Qurat Ul Ain Riaz Sipra,

Tom Lassar

Publication year - 2021

Publication title -

cardiovascular therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.818

H-Index - 46

eISSN - 1755-5922

pISSN - 1755-5914

DOI - 10.1155/2021/8886210

Subject(s) - medicine , rivaroxaban , atrial fibrillation , stroke (engine) , venous thrombosis , pulmonary embolism , coronary artery disease , thrombosis , apixaban , intensive care medicine , heart failure , disease , cardiology , warfarin , mechanical engineering , engineering

Direct oral anticoagulants (DOACs) are widely used for the prevention of stroke in nonvalvular atrial fibrillation, treatment of deep venous thrombosis and pulmonary embolism, and as prophylaxis after hip and knee surgery after approval by the Food and Drug Administration. In the last decade, DOACs were studied for various indications; this review is focused on rivaroxaban, a factor Xa inhibitor, which is used in an expanded evidence-based fashion for coronary artery disease, peripheral artery disease, heart failure, malignancy, and prophylaxis of deep venous thrombosis in acute medical illnesses.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research